H. Kölbl - Concepedia

Author

H. Kölbl

Medical University of Vienna

Also Known As

H KOLBL, H Kolbl, H Kölbl, H Kölbl, H. Kolbl, H. Kölbl, H. Kölbl, H.K. Kölbl, HEINZ KÖLBL, Heinz KOLBL

426

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Medical University of Vienna Johannes Gutenberg University Mainz University of Vienna University Medical Center of the Johannes Gutenberg University Mainz Ludwig-Maximilians-Universität München

About

H. Kölbl is an author at Medical University of Vienna specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	762
2	Health Sciences	3	3	74
3	Biochemistry	2	2	163
4	Engineering	1	1	102
5	Natural Sciences	1	1	53

H. Kölbl

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer Marcus Schmidt, Daniel Böhm, Christian von Törne, Cancer Research	2008	825
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors Martin Filipits, Margaretha Rudas, R. Jakesz, Clinical Cancer Research	2011	703
An anthelmintic compound, nafuredin, shows selective inhibition of complex I in helminth mitochondria Satoshi Ōmura, Hiroko Miyadera, Hideaki Ui, Proceedings of the National Academy of Sciences	2000	129
Argadin, a New Chitinase Inhibitor, Produced by Clonostachys sp. FO-7314. Noriko Arai, Kazuro Shiomi, Yuuici YAMAGUCHI, Chemical and Pharmaceutical Bulletin Molecular PharmacologyFungal Strain Fo-7314Cation ExchangeNew Chitinase InhibitorIndustrial Mycology	2000	110
Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach Daniel Böhm, Ksenia Keller, Julia Pieter, Oncology Reports Breast OncologyEngineeringPathologyProteomic ApproachProteomic Technology	2012	102
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial José E. Batista, H. Kölbl, Sender Herschorn, Therapeutic Advances in Urology	2015	83
Argifin, a New Chitinase Inhibitor, Produced by Gliocladium sp. FTD-0668. I. Taxonomy Fermentation, and Biological Activities. Satoshi Ōmura, Noriko Arai, Yuuichi Yamaguchi, The Journal of Antibiotics	2000	79
Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7–8 in human breast cancer Clemens Tempfer, A Lösch, Harald Heinzl, European Journal of Cancer Tumor BiologyBreast OncologyOncologyCancer RiskMedicine	1996	66
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut) Andreas du Bois, Jacobus Pfisterer, Nicole Burchardi, Gynecologic Oncology Pegylated Liposomal DoxorubicinKommission UterusMedicineGynecologyCombination Therapy	2007	59
ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer Ilka Petry, Esther Fieber, Marcus Schmidt, Clinical Cancer Research	2010	59

Page 1